Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959382 | 0.79 | THRB (0.31) | — | |
| SCHEMBL200910 | 0.71 | MEN1 (0.34) | PKM | |
| SCHEMBL30825009 | 0.66 | — | — | |
| SCHEMBL7822571 | 0.64 | SLC6A2 (0.46) | — | |
| SCHEMBL1131365 | 0.62 | CYP19A1 (0.38) | — | |
| SCHEMBL8890451 | 0.62 | — | — | |
| SCHEMBL722108 | 0.61 | LMNA (0.63) | PKM | |
| SCHEMBL5670902 | 0.61 | LMNA (0.63) | PKM | |
| SCHEMBL7436969 | 0.60 | FPR2 (0.32) | — | |
| SCHEMBL6662264 | 0.59 | MEN1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575901-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7576239-B2 | Substituted amides | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090137529-A1 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-05-28 | — | — | US | disclosed |
| EP-1575901-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2019593-A1 | PRO-DRUGS OF TERTIARY ALCOHOLS | Merck & Co., Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20080194645-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| WO-2007136571-A1 | PRO-DRUGS OF TERTIARY ALCOHOLS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20060106071-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| CN-1747926-A | Substituted amide compounds | MERCK & CO INC (US) | 2006-03-15 | — | — | CN | disclosed |
| US-6972295-B2 | Substituted amides | MERCK & CO., INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1575901-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (a New Jersey corp.) (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004058145-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | PKM 3986/4885 |
| US-20060106071-A1 | Substituted amides | CNR1, CNR2, FAAH | PKM 3986/4885 |
| US-20080194645-A1 | Substituted amides | CNR1, CNR2, FAAH | PKM 3986/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | PKM 3974/4885 |
| US-20090137529-A1 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, CHRNA10 | PKM 3747/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | PKM 3986/4885 |
| US-20050234061-A1 | Substituted amides | CNR1, CNR2, FAAH | PKM 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.